Allena Pharmaceuticals, Inc. Net Debt

Net Debt of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Net Debt growth rates and interactive chart. Net debt is the sum of all interest-bearing debt (short-term and long-term) minus cash and short-term investments. A positive number indicates the company's total debt exceeds its cash and short-term investments balances, while a negative number means the company has more cash than its total debt. This figure is also used in Enterprise value calculation.


Highlights and Quick Summary

  • Net Debt for the quarter ending March 31, 2022 was $-8.9 Million (a -54.64% decrease compared to previous quarter)
  • Year-over-year quarterly Net Debt decreased by -46.01%
  • Annual Net Debt for 2021 was $-19.6 Million (a -20.0% decrease from previous year)
  • Annual Net Debt for 2020 was $-24.5 Million (a 25.6% increase from previous year)
  • Annual Net Debt for 2019 was $-19.5 Million (a -62.23% decrease from previous year)
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Net Debt of Allena Pharmaceuticals, Inc.

Most recent Net Debtof ALNA including historical data for past 10 years.

Interactive Chart of Net Debt of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Net Debt for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $-8.9
2021 $-19.61 $-30.23 $-16.48 $-26.17 $-19.61
2020 $-24.9 $-20.1 $-18.17 $-11.04 $-24.51
2019 $-19.53 $-31.9 $-40.02 $-42.26 $-19.52
2018 $-51.66 $-60.58 $-68.87 $-81.85 $-51.66
2017 $-88.98 $-27.25 $-85.11
2016 $-39.17
2015 $-65.08 $-65.08

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.